Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 5,927 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Inferior Alveolar Nerve Injuries
Interventions: 4% Articaine with 1:200,000 epinephrine, 2% lidocaine with 1:100,000 epinephrine; Drug
Lead sponsor: Cleveland Dental Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Akron, Ohio • Ashtabula, Ohio

Conditions: Crohn Disease
Interventions: BI 706321, Ustekinumab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more

Conditions: Urinary Tract Infection, Acute Pyelonephritis
Interventions: TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Oral Leukoplakia
Interventions: pioglitazone-metformin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Chronic Myelogenous Leukemia
Interventions: Asciminib, Bosutinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 10
States / cities: Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more

Conditions: Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas, Thymoma
Interventions: Celebrex, Tumor cell vaccine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Med-eMonitor, PharmCAT, Treatment as Usual; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 60 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Head and Neck Cancer
Interventions: MLN8237, Cetuximab, Radiotherapy; Drug · Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions: Placebo, Avatrombopag tablets; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Anaheim, California • Bakersfield, California • Concord, California + 21 more

Conditions: Cystic Fibrosis
Interventions: standardized turmeric root extract; Drug
Lead sponsor: Ramsey, Bonnie, MD; Individual
Eligibility: 18 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Anal, Colon, and Rectal Cancers, Head and Neck Cancer, Lung Cancer, Colon Cancer, Colonic Neoplasms, Colorectal Neoplasms, Colon/Rectal Cancer, Colon/Rectal Cancer Colon Cancer, Colon/Rectal Cancer Rectal Cancer, Colon/Rectal Cancer Anal Cancer, Head and Neck Cancers, Head and Neck Cancers Lip, Head and Neck Cancers Oral Cavity, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oropharynx, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Trachea, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC)
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
Interventions: Suvorexant, Placebo; Drug · Other
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Ovarian Cancer
Interventions: Minoxidil; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: HIV Infection
Interventions: Tenofovir Disoproxil Fumarate 300 mg daily; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 29 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Osteoradionecrosis of the Jaw, Xerostomia
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Anemia of Chronic Kidney Disease
Interventions: Vadadustat, Erythropoiesis Stimulating Agent; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 2,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more

Conditions: Chronic Insomnia
Interventions: Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo; Drug
Lead sponsor: Somnum Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Orange City, Florida • Fayetteville, Georgia • Smyrna, Georgia + 6 more

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Atrial Fibrillation
Interventions: Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 162
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more

Conditions: Systemic Lupus Erythematosus
Interventions: GLPG3667, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more

Conditions: Gingivitis
Interventions: Interdental cleaning device with water, Interdental cleaning device with essential-oil mouthrinse; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Jaw, Edentulous, Partially
Interventions: Straumann Bone Level Implants, 4.1 mm implant diameter, Straumann Bone Level Implants, 3.3 mm implant diameter; Device
Lead sponsor: Institut Straumann AG; Industry
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more

Conditions: Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence, Alcohol-Related Disorders
Interventions: Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Placebo, Peppermint Oil, masking flavor; Dietary Supplement · Other
Lead sponsor: Endourage, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Novato, California

Search by objective public record fields.

Risk of Nerve Damage After Administration of Local Anesthesia

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia

MLN8237 in Head and Neck Cancer

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors

Suvorexant for Treatment of AUD and PTSD

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Botswana Tenofovir Oral HIV Prophylaxis Trial

Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study

Vafseo Outcomes In-Center Experience

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia in a Randomized, Controlled, Dose-finding Study

Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

A Study to Determine the Effects of Adding an Experimental Device With Mouthrinse to Oral Care Regimen

Straumann Roxolid Multi-Center Study

Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use